March Highlights qFibrosis® Revealing New Insights into Treatment Response with Resmetirom in the MAESTRO-NASH Phase 3 Study qFibrosis® once again takes center stage in advancing our understanding of fibrosis in MASH. A recent Journal of Hepatology publication, “Quantitative regression of qFibrosis with resmetirom: Exploratory histologic endpoints from the MAESTRO-NASH Phase III clinical trial,” highlights how […]
Newsletter (March 2026) Read More »
As Metabolic Dysfunction-associated Steatohepatitis (MASH) continues to rise in both clinical prevalence and therapeutic focus, the demand for accurate, reproducible, and scalable fibrosis assessment has intensified. Fibrosis remains the most critical histological feature for staging disease severity, predicting outcomes, and evaluating treatment response. Traditionally, liver biopsy evaluation has relied on expert interpretation, an approach that,
February Highlights qFibrosis® Uncovers Divergent Collagen Remodeling Across Liver Disease Subtypes A recent study conducted by Seoul National University Boramae Medical Center and Kyung Hee University Hospital provides new insights into fibrosis progression across steatotic liver disease subtypes. Now published in Gastroenterology, the study utilized HistoIndex’s fibrosis quantification algorithm, qFibrosis®, to identify distinct patterns of
Newsletter (February 2026) Read More »
Advancing MASH Diagnostics Through Strategic Partnerships January 20, 2026 – HistoIndex is set to expand its footprint in clinical hepatology and gastroenterology through new commercial partnerships with leading medical centers in the US and Europe. These collaborations unlock our unique diagnostic offering, which combines standard histopathological evaluation by expert pathologists with AI-driven biopsy analysis. Such
Newsletter (January 2026) Read More »
HistoIndex Partners with Houston Research Institute to Expand Advanced MASH Diagnostic Services SINGAPORE, Jan. 21, 2026 /PRNewswire/ — HistoIndex, a pioneer in AI-driven digital pathology solutions for chronic liver disease, has announced a strategic partnership with Houston Research Institute (HRI). HRI is a leading research institute focused on conducting clinical trials in hepatology and gastroenterology, with a
HistoIndex to Debut FibroSIGHT™ Plus and Showcase Latest Scientific Findings at AASLD The Liver Meeting® 2025 SINGAPORE, Oct. 15, 2025 /PRNewswire/ — HistoIndex, a pioneering leader in digital pathology solutions for chronic liver disease, is returning to The Liver Meeting® (TLM) 2025, hosted by the American Association for the Study of Liver Diseases (AASLD). The conference, which
HistoIndex Marks Another Step Forward with FibroSIGHT™ Plus: Introducing AI-based Quantitative Analysis in Fibrosis Assessment SINGAPORE, Aug. 10, 2025 /PRNewswire/ — HistoIndex, a pioneering leader in digital pathology solutions for chronic liver disease, has announced the launch of FibroSIGHT™ Plus, its second Laboratory Developed Test (LDT) available in the United States. Building on the foundation of FibroSIGHT™[1], which debuted
HistoIndex Secures SGD 9 Million Investment to Drive Next Phase of Expansion SINGAPORE, May 2, 2025 /PRNewswire/ — HistoIndex, known for its groundbreaking biophotonic Second Harmonic Generation (SHG) technology and a pioneering leader in Artificial Intelligence (AI) digital pathology for the management of fibrotic diseases, has announced the close of a S$9 million investment round to support its next
HistoIndex Secures SGD9 Million Investment to Drive Next Phase of Expansion Read More »
A New Standard in Clinical Care for MASH Patients: HistoIndex Launches FibroSIGHT™ SINGAPORE, March 17, 2025 /PRNewswire/ — HistoIndex, a global leader in stain-free digital pathology solutions for managing fibrotic diseases, has announced the launch of their first Laboratory Developed Test (LDT) FibroSIGHT™ – now available in the United States. This marks a significant milestone
A New Standard in Clinical Care for MASH Patients: HistoIndex Launches FibroSIGHT™ Read More »
BRIDGING CLINICAL RESEARCH AND CLINICAL CARE WITH AI-AIDING PATHOLOGISTS TOOL SINGAPORE, Dec. 9, 2024 /PRNewswire/ — A newly published collaborative study[1] in the Journal of Hepatology, featuring HistoIndex – a global leader in stain-free digital pathology solutions for managing fibrotic diseases – alongside Merck & Co., MSD, Virginia Commonwealth University (VCU), The National Institutes of Health (NIH) and a panel of distinguished international
Bridging Clinical Research and Clinical Care with AI-aiding Pathologists Tool Read More »
©2026 Histoindex Pte Ltd. All Rights Reserved. All logos and trademarks are the property of HistoIndex or their respective owners.